Navigation Links
Proteon Therapeutics Completes $38M Equity Financing; Initiates Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients and Signs Option Agreement With Major Pharmaceutical Company
Date:3/5/2009

WALTHAM, Mass., March 5 /PRNewswire/ -- Proteon Therapeutics, Inc., announced today that it has successfully completed a $38 million Series B equity financing, led by MPM Capital on behalf of the MPM Bio IV NVS Strategic Fund L.P. This announcement follows the initiation of a Phase 1/2 human clinical study of its lead product, PRT-201, in patients with end stage renal disease undergoing surgery for arteriovenous fistula (AVF) creation. Additionally, Proteon further bolstered its cash reserves by entering into an agreement with Novartis whereby Novartis has been granted an exclusive option to acquire Proteon following the successful completion of a Phase 2 clinical study of PRT-201 with a potential secondary right to a global license under pre-agreed conditions. Including the initial acquisition payment plus potential additional regulatory milestone payments, the deal with Novartis could exceed $550 million.

The Series B financing includes new investors, the MPM Bio IV NVS Strategic Fund L.P. and the Vectis Healthcare & Life Sciences Fund, along with existing investors TVM Capital, Skyline Ventures, Prism VentureWorks, Intersouth Partners and several of Proteon's original angel investors. Concurrent with the investment, Proteon also announced the addition of Dr. Steven St. Peter, Managing Director of MPM Capital, to the Proteon Therapeutics Board of Directors.

"Patients with kidney failure endure great suffering and frequent hospitalization due to vascular access complications. If successful, PRT-201 may improve medical outcomes and lower the associated cost of care," said Timothy P. Noyes, President and CEO of Proteon. "We greatly appreciate the continued support of our existing venture and angel investors, and we are excited to welcome MPM and Vectis as new investors." The combination of the Novartis option agreement and the closing of the Series B financing will allow Proteon to develop PRT-201 through Phase 2.


'/>"/>
SOURCE Proteon Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Proteon Therapeutics to Present New Data on PRT-201 at Transcatheter Cardiovascular Therapeutics (TCT) Annual Symposium in Washington, D.C., October 13, 2008
2. National Stem Cell Holding, Inc. Announces the Change of Its Name to Proteonomix, Inc.
3. Proteon Therapeutics Receives European Patent Covering New Method of Dilating Arteries and Veins
4. Proteon Therapeutics Appoints Experienced Biopharmaceutical Executive, Gregory D. Phelps to its Board of Directors
5. Proteon Therapeutics to Present at Annual Meeting of American Society of Nephrology in San Francisco on November 2, 2007
6. Proteon Therapeutics Completes $12 Million Financing and Hires CFO
7. Pharmexa and Affitech to Combine Operations to Create a New Antibody Therapeutics Company
8. ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results
9. Pearl Therapeutics Appoints Perry Karsen as Chief Executive Officer
10. CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas Tender Offer
11. Cornerstone Therapeutics to Host Quarter and Year Ended December 31, 2008 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 2013 As the R&D sector ... within the industry to deliver better products, faster. ... pharma companies often means turning big ideas into ... in collaboration with Sensidose AB and Recipharm, is ... products to market sooner. The partnership resulted in ...
(Date:5/21/2013)... 21, 2013  MacroGenics, Inc. today announced that ... (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), in ... oncoprotein," will be presented at the 2013 Annual ... during the Developmental Therapeutics - Immunotherapy Oral Abstract ... 4:30 PM.  The presentation will describe the results ...
(Date:5/21/2013)... Bed bugs have become so widespread in the ... turn to chemical-based pesticides for help to completely get rid ... those solutions present, the company advised the public to ... , According to My Cleaning Products, chemical-based pesticides are not ... It shared that the pests have already developed immunity to ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Inflamax ... of the ITN to design the study, which ... two key clinical models used in the study ... and Nasal Allergen Challenge (NAC) models. Although both ... numerous publications, to date no direct comparison between ...
Breaking Biology Technology:The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 2New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 3Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation. 2
... Importance of Allergy Testing in Managing Chronic ... ... Phadia US Inc. announced today,that The National Asthma Education and Prevention ... for the Diagnosis and,Management of Asthma. Information in the guidelines reported ...
... steps ... towards public reporting status., SAN ANTONIO, Aug. 30 ... targeted cancer therapies with improved efficacy and reduced toxicity,announced the ... a control position in a public reporting shell company. ...
... Aug. 30 Pressure,BioSciences, Inc. (Nasdaq: ... has been,issued its first patent by the ... Biomolecular Complexes" (Number,2,259,318), this issuance extends the ... patents previously issued in the United States,Japan, ...
Cached Biology Technology:Updated NIH Guidelines Offer Valuable Information on Asthma Diagnosis and Management 2OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company 2Pressure BioSciences, Inc. Issued First Patent in Canada 2Pressure BioSciences, Inc. Issued First Patent in Canada 3
(Date:5/21/2013)... is an uphill battle? Try staying fit in space, ... muscle and bone. , That,s the challenge a group ... new three-year, $1.2 million grant from NASA. Their goal ... exploratory missions. , "You could give astronauts the best ... them to stick to it, it isn,t going to ...
(Date:5/21/2013)... Royal Philips Electronics (NYSE: PHG, AEX: PHIA) ... ultrasound with Philips, industry leading Live 3D TEE, now ... with available Live 3D TEE and ICE will be ... EuroPCR, official meeting for the European Association of Percutaneous ... launch in 2012, Philips CX50 xMATRIX has been the ...
(Date:5/20/2013)... The Amazon rain forest, popularly known as the lungs of ... use carbon dioxide from the air to grow parts that ... away by the region,s plentiful rainfall. , Until recently ... the Amazon River and ended up deep in the ocean. ... exhale huge amounts of carbon dioxide though left open ...
Breaking Biology News(10 mins):Fueling fitness on the final frontier 2Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system 2Amazon River exhales virtually all carbon taken up by rain forest 2Amazon River exhales virtually all carbon taken up by rain forest 3
... Kimmel Award for Innovative Investigation on Monday, Nov. 5 at ... grant of a million dollars over five years. Taking ... the impulses that drive evolution. Living cells are, from this ... have all sorts of interesting consequences for many other molecules ...
... all" when it comes to weight loss through exercise, says ... Neil King, from QUT,s Institute of Health and Biomedical Innovation, ... with the University of Leeds in the UK, which has ... of Obesity. "When it comes to losing weight, a ...
... issue of BioScience describes the history and summarizes the ... surface and substrate. , Although more expensive to construct ... energy costs during a buildings lifetime and control storm-water ... structures are currently less common in the United States ...
Cached Biology News:Weizmann Institute scientists discover: A 'risk distribution law' for evolution 2Weight loss -- not one size fits all 2
Normal human serum collected off the clot from healthy normal humans. Each donor unit is negative for anti-HIV 1&2, HIV-Ag, HCV, and HBsAg by FDA required tests...
sterile filtered, off the clot, all male donors, Total Protein: 4.5 to 8.5 g/dl...
Recombinant Mouse MMP-9, CF...
Human/Mouse/Rat JNK Pan Specific Affinity Purified PAb...
Biology Products: